Key Product Details

Species Reactivity

Human

Applications

Immunohistochemistry, Western Blot, Neutralization

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG
View all TAFA1/FAM19A1 Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human TAFA1/FAM19A1
Ser26-Thr133
Accession # NP_998774

Specificity

Detects human TAFA1/FAM19A1 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant human (rh) TAFA3 and rhTAFA4 is observed, less than 10% cross-reactivity with rhTAFA2 is observed and less than 1% cross-reactivity with rhTAFA5 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human TAFA1/FAM19A1 Antibody

TAFA1/FAM19A1 antibody in Human Brain by Immunohistochemistry (IHC-P).

TAFA1/FAM19A1 in Human Brain.

TAFA1/FAM19A1 was detected in immersion fixed paraffin-embedded sections of human brain (cortex) using Goat Anti-Human TAFA1/FAM19A1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5154) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling when primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Detection of TAFA1/FAM19A1 by Western Blot

Detection of TAFA1/FAM19A1 by Western Blot

The inhibition of FAM19A1 promotes stemness and proliferation of NSCs. (A) Bright field microscopy of neurospheres in si-FAM19A1 and control group, n = 6, Scale bar = 500 μm. (B) EdU labeling in si-FAM19A1 and control group, n = 6, Scale bar = 100, 50 μm. (C) Corresponding quantifications and statistics of (A,B). (D) RT-qPCR of FAM19A1 and stemness markers Sox2, Nestin, Pax6, CD133, and glast, n = 4. (E) Western blotting analysis of Sox2, Nestin, and Pax6, n = 4. (F) Corresponding quantifications and statistics of (E). For statistical analysis, *p < 0.05, **p < 0.01, compared with the NC-siRNA group. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of TAFA1/FAM19A1 by Western Blot

Detection of TAFA1/FAM19A1 by Western Blot

si-FAM19A1 could rescue weakened stemness and proliferation of NSCs caused by miR-582-5p inhibitor. (A) Bright field microscopy of neurospheres in the NC-inhibitor and NC-siRNA co-transfection group, the NC-inhibitor and si-FAM19A1 group, the miR-582-5p inhibitor and NC-siRNA group, and the miR-582-5p inhibitor and si-FAM19A1 group, n = 6, Scale bar = 500 μm. (B) EdU labeling of the four groups, n = 6, Scale bar = 100, 50 μm. (C) Corresponding quantifications and statistics of A and B. Two-way ANOVA with Dunnett’s test. (D) RT-qPCR of stemness markers Sox2, Nestin, Pax6, CD133, and glast, n = 3. Two-way ANOVA with Dunnett’s test. (E) Western blotting analysis of Sox2, Nestin, and Pax6, n = 5. (F) Corresponding quantifications and statistics of E. Two-way ANOVA with Dunnett’s test. For statistical analysis, *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control, respectively. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of TAFA1/FAM19A1 by Western Blot

Detection of TAFA1/FAM19A1 by Western Blot

miR-582-5p down-regulates the expression of FAM19A1. (A) RNA-seq of miR-582-5p mimic and NC-mimic transfected NSCs, n = 3. (B) The mRNA expression of potential target genes in the mimic and NC-mimic group, with FAM19A1 down-regulated, n = 4. (C) RT-qPCR analysis of FAM19A1 in the inhibitor and NC-inhibitor group, n = 7. (D) RT-qPCR analysis of FAM19A1 in the GSI and control DMSO group, n = 6. (E,E’) Western blotting and statistics of FAM19A1 in the mimic/inhibitor and control group, n = 4. (F) The sequence of the FAM19A1 3′UTR and the binding site of miR-582-5p (red font). (G) The relative luciferase activity of the FAM19A1 3′UTR reporter with the increase of miR-582-5p concentration, n = 3. One-way ANOVA with Dunnett’s test. (H) The expression of firefly luciferase mRNA with the increase of miR-582-5p concentration, n = 4. One-way ANOVA with Dunnett’s test. For statistical analysis, *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control, respectively. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of TAFA1/FAM19A1 by Western Blot

Detection of TAFA1/FAM19A1 by Western Blot

The inhibition of FAM19A1 promotes stemness and proliferation of NSCs. (A) Bright field microscopy of neurospheres in si-FAM19A1 and control group, n = 6, Scale bar = 500 μm. (B) EdU labeling in si-FAM19A1 and control group, n = 6, Scale bar = 100, 50 μm. (C) Corresponding quantifications and statistics of (A,B). (D) RT-qPCR of FAM19A1 and stemness markers Sox2, Nestin, Pax6, CD133, and glast, n = 4. (E) Western blotting analysis of Sox2, Nestin, and Pax6, n = 4. (F) Corresponding quantifications and statistics of (E). For statistical analysis, *p < 0.05, **p < 0.01, compared with the NC-siRNA group. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of TAFA1/FAM19A1 by Western Blot

Detection of TAFA1/FAM19A1 by Western Blot

si-FAM19A1 could rescue weakened stemness and proliferation of NSCs caused by miR-582-5p inhibitor. (A) Bright field microscopy of neurospheres in the NC-inhibitor and NC-siRNA co-transfection group, the NC-inhibitor and si-FAM19A1 group, the miR-582-5p inhibitor and NC-siRNA group, and the miR-582-5p inhibitor and si-FAM19A1 group, n = 6, Scale bar = 500 μm. (B) EdU labeling of the four groups, n = 6, Scale bar = 100, 50 μm. (C) Corresponding quantifications and statistics of A and B. Two-way ANOVA with Dunnett’s test. (D) RT-qPCR of stemness markers Sox2, Nestin, Pax6, CD133, and glast, n = 3. Two-way ANOVA with Dunnett’s test. (E) Western blotting analysis of Sox2, Nestin, and Pax6, n = 5. (F) Corresponding quantifications and statistics of E. Two-way ANOVA with Dunnett’s test. For statistical analysis, *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control, respectively. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of TAFA1/FAM19A1 by Western Blot

Detection of TAFA1/FAM19A1 by Western Blot

miR-582-5p down-regulates the expression of FAM19A1. (A) RNA-seq of miR-582-5p mimic and NC-mimic transfected NSCs, n = 3. (B) The mRNA expression of potential target genes in the mimic and NC-mimic group, with FAM19A1 down-regulated, n = 4. (C) RT-qPCR analysis of FAM19A1 in the inhibitor and NC-inhibitor group, n = 7. (D) RT-qPCR analysis of FAM19A1 in the GSI and control DMSO group, n = 6. (E,E’) Western blotting and statistics of FAM19A1 in the mimic/inhibitor and control group, n = 4. (F) The sequence of the FAM19A1 3′UTR and the binding site of miR-582-5p (red font). (G) The relative luciferase activity of the FAM19A1 3′UTR reporter with the increase of miR-582-5p concentration, n = 3. One-way ANOVA with Dunnett’s test. (H) The expression of firefly luciferase mRNA with the increase of miR-582-5p concentration, n = 4. One-way ANOVA with Dunnett’s test. For statistical analysis, *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control, respectively. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human TAFA1/FAM19A1 Antibody

Application
Recommended Usage

Immunohistochemistry

5-15 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human brain (cortex)

Western Blot

0.1 µg/mL
Sample: Recombinant Human TAFA1/FAM19A1 (Catalog # 5154-TA)

Neutralization

Measured by its ability to neutralize the enhancement of neurite outgrowth of cortical neurons from E16E18 rat embryos induced by TAFA1. Neurite outgrowth is inhibited at 15 µg/mL in the presence of 10 µg/mL Recombinant Human TAFA1.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Sterile PBS to a final concentration of 0.2 mg/mL. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: TAFA1/FAM19A1

TAFA1 (also FAM19A1) is a secreted, 13 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 133 amino acid (aa) precursor that contains a 19 aa signal sequence and a 114 aa mature chain. Like other members of the FAM19/TAFA family, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern CX7CCX13CXCX14CX11CX4CX5CX10C, in which C represents a conserved cysteine residue and X represents a noncysteine amino acid (1). Human TAFA1 is 100% aa identical to mouse TAFA1. TAFA1 is expressed exclusively in the brain, with highest expression in the frontal cortex, temporal cortex, occipital cortex, parietal cortex and medulla, and low levels in the basal ganglion, thalamus, and cerebellum (1). The biological functions of TAFA family members remain to be determined, but there are a few tentative hypotheses. First, TAFAs may modulate immune responses in the CNS by functioning as brain-specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1, 2). And third, TAFAs may control axonal sprouting following brain injury (1).

References

  1. Tang, Y.T. et al. (2004) Genomics 83:727.
  2. Benveniste, E. (1998) Cytokine Growth Factor Rev. 9:259.

Long Name

Family with Sequence Similarity 19, Member A1

Alternate Names

FAM19A1

Entrez Gene IDs

407738 (Human); 320265 (Mouse); 500266 (Rat)

Gene Symbol

TAFA1

UniProt

NP_998774

Additional TAFA1/FAM19A1 Products

Product Documents for Human TAFA1/FAM19A1 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human TAFA1/FAM19A1 Antibody

For research use only

Citations for Human TAFA1/FAM19A1 Antibody

Customer Reviews for Human TAFA1/FAM19A1 Antibody

There are currently no reviews for this product. Be the first to review Human TAFA1/FAM19A1 Antibody and earn rewards!

Have you used Human TAFA1/FAM19A1 Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies